Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03410719 · ClinicalTrials.gov registry record · NA
Mediterranean Style Diet and Low Glycemic Responses
A NA study of Insulin Sensitivity, sponsored by Purdue University.
- Completed
- Registry status
- NA
- Development phase
- 166
- Enrollment target
- 1
- Study location
NCT03410719: Completed NA study of Insulin Sensitivity, sponsored by Purdue University.
NCT03410719 is a NA study of Insulin Sensitivity that has completed, run by Purdue University. The registered enrollment target is 166 participants, above the 67-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (148% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03410719, a NA study of Insulin Sensitivity, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- NA
- Development phase
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
the aim of this study is to evaluate whether a Mediterranean diet rich in pasta and other starchy foods with a (Low-GI), as compared with a similar Mediterranean diet containing very little pasta and based on starchy foods with a (Hi-GI) is able to reduce insulin and glucose concentrations during a prolonged test study meal.
Primary Outcome
All subjects will consume the same quantities of metabolizable carbohydrate (270 g/d) with 135 g of carbohydrates assigned to the GI intervention foods. The 135 g of carbohydrates will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Fiber is set as 35 g/d for both intervention groups. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half o
Conditions Studied
Interventions
- OTHER Hi GI
Study Locations (1)
Indiana
- Purdue University - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2018-01-04 |
| Est. Completion | 2020-03-21 |
| Phase | NA |
What the finished NCT03410719 record still lists
NCT03410719 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 67-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (148% higher).
The record links to 1 condition, with Insulin Sensitivity appearing as the primary indexed condition, and to 1 intervention - of which Hi GI is the first listed.
NCT03410719 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03410719 about?
NCT03410719 is a clinical study titled "Mediterranean Style Diet and Low Glycemic Responses". the aim of this study is to evaluate whether a Mediterranean diet rich in pasta and other starchy foods with a (Low-GI), as compared with a similar Mediterranean diet containing very little pasta and based on starchy foods with a (Hi-GI) is able to reduce insulin and glucose concentrations during a ...
What is the current status of trial NCT03410719?
This trial is currently completed. It is a NA study. The enrollment target is 166 participants. The study started on 2018-01-04. Estimated completion is 2020-03-21.
What conditions does trial NCT03410719 study?
This clinical trial studies the following conditions: Insulin Sensitivity.
What interventions are being tested in trial NCT03410719?
The interventions under investigation include: Hi GI (OTHER).
Who is sponsoring clinical trial NCT03410719?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03410719 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Sensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03410719's enrollment target sits among peer trials
166 2nd of 29 the highest of 29 other Insulin Sensitivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Sensitivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Countermeasures to Circadian Misalignment
RECRUITING · NA
-
Effect of Pulsatile Hormone Administration on Insulin Action
RECRUITING · NA
-
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
RECRUITING · NA
-
Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI